Related Experiment Video
Updated: Apr 19, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left atrial appendage occlusion
1The Division of Cardiovascular Diseases and Department of Internal Medicine, University of Alabama, Birmingham, Alabama, USA The Division of Cardiovascular Diseases and Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.
Insights
Left atrial appendage (LAA) occlusion is a promising stroke prevention strategy for atrial fibrillation (AF) patients. While safe and effective, more data is needed for widespread adoption.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Thrombosis Research
Background:
- Atrial fibrillation (AF) poses a significant risk of stroke and thromboembolism.
- The left atrial appendage (LAA) is a primary source of thrombus formation in AF patients.
- Current management focuses on pharmacological stroke prevention, with LAA occlusion as an alternative.
Purpose of the Study:
- To review the current status of LAA occlusion for stroke prevention in AF.
- To analyze existing clinical data, available techniques, and devices.
- To discuss challenges and future directions for LAA occlusion strategies.
Main Methods:
- Review of current clinical data and randomized trials on LAA occlusion.
- Analysis of various percutaneous and surgical LAA occlusion devices and techniques.
- Evaluation of safety, efficacy, cost-effectiveness, and long-term outcomes.
Main Results:
- LAA occlusion is demonstrated to be a safe and effective stroke prevention method.
- Challenges to adoption include limited randomized trial data, cost-effectiveness concerns, and procedural risks.
- Various percutaneous and surgical devices are available for LAA exclusion.
Conclusions:
- LAA occlusion is a viable alternative for stroke prevention in select AF patients.
- Further high-quality clinical trial data is essential to support broader adoption.
- Addressing cost-effectiveness and long-term outcomes will be crucial for future development.
Abstract:
Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a significant advancement in the field of cardiovascular disease. Prevention and avoidance of the devastating consequences of thromboembolic complications from AF continues to be central in the management of these patients. The role of LAA as a nidus for thrombus formation is well documented. Multiple approaches to exclude the LAA from the circulation either percutaneously or surgically have been described and are undergoing testing. Although pharmacological therapy for stroke prevention remains the cornerstone of treatment, device and surgical exclusion of the LAA have proven to be viable alternatives in carefully selected patients. Even though current evidence show that LAA occlusion is safe and effective, approval and adoption of this strategy has been quite difficult due to paucity of randomised clinical trial data on the risk and benefit ratio, cost effectiveness and the issues of procedural risk as well as longer-term outcome. This review aims to provide an update on the current status of LAA occlusion, specifically looking at interpretation of current clinical data, available techniques and devices, issues with current devices and future direction.
